In a recent Phase IIB clinical trial, intranasal insulin (INI) delivered to the brain of AD patients162 improved AD biomarker profiles and inflammation163 while slowing vascular damage indicated by slowed white matter hyperintensity progression.164. Here, INS is linked to Alzheimer disease.